Menu
← Oncology Approval Tracker
FDA DECISION ·
Alymsys
bevacizumab-maly · Amneal Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Bevacizumab biosimilar for labeled uses in metastatic colorectal cancer, nonsquamous NSCLC, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent or metastatic cervical cancer.
LAMPGEN ANALYSIS
Why it matters
This adds a bevacizumab product for established labeled oncology regimens.
What research teams should watch
Check the product-specific label, treatment partner and formulary authorization for each disease setting.
PRIMARY RECORDS